Pro Medicus (PME) AGM 2025 summary

Opening remarks and agenda

• The meeting was held in a hybrid format, with both physical and online attendance options available for shareholders.

• Acknowledgement was made of the traditional owners of the land and the transition to a new online meeting platform.

• The chairman introduced the board, executive team, and key personnel, highlighting their roles and contributions.

• Celebrated another highly successful year, attributing achievements to technology, management, and staff dedication.

• Highlighted the company's robust business model and ongoing commitment to service excellence.

Financial performance review

• Fiscal 2025 saw revenue rise 31.9% to AUD 213 million and net profit after tax increase 39.2% to AUD 115.2 million.

• Underlying EBIT reached AUD 157.7 million, up 40.5%, with a 74% EBIT margin.

• Cash and liquid investments grew to AUD 210.7 million after a share buyback and increased dividends, up 35.5%.

• The company remains debt-free and maintains a high proportion of recurring revenue.

• Results to date in fiscal 2026 are ahead of budget, with strong momentum expected in the second half.

Board and executive committee updates

• The board is expanding its skills and anticipates adding new directors in the next year or two.

• Non-executive director remuneration cap was increased to AUD 2 million to allow for board growth.

• Directors emphasized their commitment to governance and accountability.

• Management team, led by Dr. Sam Hupert, recognized for long-term stability and expertise.

• Board continues to invest in staff and management in line with strategic objectives.